Related references
Note: Only part of the references are listed.Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis
Alessandro Rizzo et al.
FUTURE ONCOLOGY (2020)
HLA-corrected tumor mutation burden and homologous recombination de fi ciency for the prediction of response to PD -(L)1 blockade in advanced non -small -cell lung cancer patients
J. H. Shim et al.
ANNALS OF ONCOLOGY (2020)
Molecular targeted therapies: Ready for prime time in biliary tract cancer
Angela Lamarca et al.
JOURNAL OF HEPATOLOGY (2020)
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
Richard D. Kim et al.
JAMA ONCOLOGY (2020)
Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow
Alessandro Rizzo et al.
ANTICANCER RESEARCH (2020)
Molecular profile of BRCA-mutated biliary tract cancers
Gilbert Spizzo et al.
ESMO OPEN (2020)
Targeting cholangiocarcinoma
Joachim C. Mertens et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication
Steven Lemery et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors
Solmaz Sahebjam et al.
CANCER CONTROL (2017)
Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma
Yun Shin Chun et al.
CANCER CONTROL (2017)
Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028
Y. J. Bang et al.
EUROPEAN JOURNAL OF CANCER (2015)
PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy
Dawn E. Dolan et al.
CANCER CONTROL (2014)
Share Paper
